Portola Pharma Investors Want Class Status for Securities Suit

Portola Pharmaceuticals Inc. investors who say the company misled them about its Andexxa coagulant want permission to move forward with their suit as a class, they told a federal judge in California.

The biopharma company’s investors seek to certify a class of everyone who acquired Portola’s common stock from Jan. 8, 2019, through and including Feb. 28, 2020, and lost money as a result. There would be exceptions for those with certain close ties to the company, according to documents filed as part of the investors’ class certification bid in the U.S. District Court for the Northern District of California. ...